A switch of G protein-coupled receptor binding preference from phosphoinositide 3-kinase (PI3K)-p85 to filamin a negatively controls the PI3K pathway

Molecular and Cellular Biology

Volumn 32, Issue 5, 2012, Pages 1004-1016

  Najib, Souad ^a,b   Saint Laurent, Nathalie ^a,b   Estève, Jean Pierre ^a,b   Schulz, Stefan ^c   Boutet Robinet, Elisa ^a,b   Fourmy, Daniel ^a,b   Lättig, Jens ^a,b   Mollereau, Catherine ^b,d   Pyronnet, Stéphane ^a,b   Susini, Christiane ^a,b   Bousquet, Corinne ^a,b  

^a CANCER RESEARCH CENTER OF TOULOUSE   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c JENA UNIVERSITY HOSPITAL   (Germany)

^d INSTITUT DE PHARMACOLOGIE ET DE BIOLOGIE STRUCTURALE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FILAMIN A; G PROTEIN COUPLED RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P85; SOMATOSTATIN G PROTEIN COUPLED RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE SILENCING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; BINDING SITES; BINDING, COMPETITIVE; CELL LINE; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; CONTRACTILE PROTEINS; MICROFILAMENT PROTEINS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN SUBUNITS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84857149883     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.06252-11     Document Type: Article

References (57)

1. Asnacios A, et al. 2008. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors. J. Clin. Oncol. 26:963-970.
2. Benali N, et al. 2000. Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc. Natl. Acad. Sci. U. S. A. 97:9180-9185.
3. Bockaert J, Fagni L, Dumuis A, Marin P. 2004. GPCR interacting proteins (GIP). Pharmacol. Ther. 103:203-221.
4. Bousquet C, et al. 2006. Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway.EMBOJ. 25:3943-3954.
5. Bunney TD, Katan M. 2010. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat. Rev. Cancer. 10:342-352.
6. Buscail L, et al. 1995. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc. Natl. Acad. Sci. U. S. A. 92:1580 -1584.
7. Buscail L, et al. 1996. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res. 56:1823-1827.
8. Carracedo A, Pandolfi PP. 2008. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27:5527-5541.
9. Cuevas BD, et al. 2001. Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase. J. Biol. Chem. 276: 27455-27461.
10. Cunningham CC, et al. 1992. Actin-binding protein requirement for cortical stability and efficient locomotion. Science 255:325-327.
11. Delesque N, et al. 1997. sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res. 57:956-962.
12. Dyson JM, et al. 2001. The SH2-containing inositol polyphosphate 5-phosphatase, SHIP-2, binds filamin and regulates submembraneous actin. J. Cell Biol. 155:1065-1079.
13. Ehrlicher AJ, Nakamura F, Hartwig JH, Weitz DA, Stossel TP. 2011. Mechanical strain in actin networks regulates FilGAP and integrin binding to filamin A. Nature 478:260 -263.
14. Feng S, Lu X, Kroll MH. 2005. Filamin A binding stabilizes nascent glycoprotein Ibalpha trafficking and thereby enhances its surface expression. J. Biol. Chem. 280:6709-6715.
15. Feng Y, Walsh CA. 2004. The many faces of filamin: a versatile molecular scaffold for cell motility and signalling. Nat. Cell Biol. 6:1034 -1038.
16. Ferjoux G, et al. 2003. Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation. Mol. Biol. Cell 14:3911-3928.
17. Florio T. 2008. Somatostatin/somatostatin receptor signalling: phosphotyrosine phosphatases. Mol. Cell. Endocrinol. 286:40-48.
18. Guillermet J, et al. 2003. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc. Natl. Acad. Sci. U. S. A. 100:155-160. Epub 2002 Dec 2018.
19. Hjalm G, MacLeod RJ, Kifor O, Chattopadhyay N, Brown EM. 2001. Filamin-A binds to the carboxyl-terminal tail of the calcium-sensing receptor, an interaction that participates in CaR-mediated activation of mitogen-activated protein kinase. J. Biol. Chem. 276:34880-34887.
20. Hortala M, et al. 2003. Inhibitory role of the somatostatin receptor SST2 on the intracrine-regulated cell proliferation induced by the 210-amino acid fibroblast growth factor-2 isoform: implication of JAK2. J. Biol. Chem. 278:20574 -20581.
21. Kiema T, et al. 2006. The molecular basis of filamin binding to integrins and competition with talin. Mol. Cell 21:337-347.
22. Kobilka BK, Deupi X. 2007. Conformational complexity of G-proteincoupled receptors. Trends Pharmacol. Sci. 28:397- 406.
23. Lad Y, et al. 2008. Structural basis of the migfilin-filamin interaction and competition with integrin beta tails. J. Biol. Chem. 283:35154 -35163.
24. Lahlou H, et al. 2003. sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J. Biol. Chem. 278:39356 -39371.
25. Lappano R, Maggiolini M. 2011. G protein-coupled receptors: novel targets for drug discovery in cancer. Nat. Rev. Drug Discov. 10:47- 60.
26. Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S. 2009. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro. J. Clin. Endocrinol. Metab. 94:654-661.
27. Li C, et al. 2009. Binding of pro-prion to filamin A disrupts cytoskeleton and correlates with poor prognosis in pancreatic cancer. J. Clin. Invest. 119:2725-2736.
28. Lin R, Karpa K, Kabbani N, Goldman-Rakic P, Levenson R. 2001. Dopamine D2 and D3 receptors are linked to the actin cytoskeleton via interaction with filamin A. Proc. Natl. Acad. Sci. U. S. A. 98:5258-5263.
29. Liu G, et al. 1997. Cytoskeletal protein ABP-280 directs the intracellular trafficking of furin and modulates proprotein processing in the endocytic pathway. J. Cell Biol. 139:1719-1733.
30. Magalhaes AC, Dunn H, Ferguson SS. 2011. Regulation of G proteincoupled receptor activity, trafficking and localization by GPCR-interacting proteins. Br. J. Pharmacol. doi:10.1111/j.1476-5381.2011.01552.x.
31. Mollereau C, Mazarguil H, Zajac JM, Roumy M. 2005. Neuropeptide FF (NPFF) analogs functionally antagonize opioid activities in NPFF2 receptor-transfected SH-SY5Y neuroblastoma cells. Mol. Pharmacol. 67: 965-975.
32. Mouledous L, et al. 2005. Long-term morphine treatment enhances proteasome-dependent degradation of G beta in human neuroblastoma SH-SY5Y cells: correlation with onset of adenylate cyclase sensitization. Mol. Pharmacol. 68:467- 476.
33. Nakamura F, et al. 2006. The structure of the GPIb-filamin A complex. Blood 107:1925-1932.
34. Nakamura F, Stossel TP, Hartwig JH. 2011. The filamins: organizers of cell structure and function. Cell Adh. Migr. 5:160-169.
35. Nieves B, et al. 2010. The NPIY motif in the integrin beta1 tail dictates the requirement for talin-1 in outside-in signaling. J. Cell Sci. 123:1216 -1226.
36. Onoprishvili I, et al. 2003. Interaction between the mu opioid receptor and filamin A is involved in receptor regulation and trafficking. Mol. Pharmacol. 64:1092-1100.
37. Popowicz GM, Schleicher M, Noegel AA, Holak TA. 2006. Filamins: promiscuous organizers of the cytoskeleton. Trends Biochem. Sci. 31: 411-419.
38. Pyronnet S, et al. 2008. Antitumor effects of somatostatin. Mol. Cell. Endocrinol. 286:230 -237.
39. Rey O, Young SH, Yuan J, Slice L, Rozengurt E. 2005. Amino acidstimulated Ca2+oscillations produced by the Ca2+-sensing receptor are mediated by a phospholipase C/inositol 1,4,5-trisphosphate-independent pathway that requires G12, Rho, filamin-A, and the actin cytoskeleton. J. Biol. Chem. 280:22875-22882.
40. Ritter SL, Hall RA. 2009. Fine-tuning of GPCR activity by receptorinteracting proteins. Nat. Rev. Mol. Cell Biol. 10:819-830.
41. Robertson SP. 2005. Filamin A: phenotypic diversity. Curr. Opin. Genet. Dev. 15:301-307.
42. Scott MG, et al. 2006. Cooperative regulation of extracellular signalregulated kinase activation and cell shape change by filamin A and betaarrestins. Mol. Cell. Biol. 26:3432-3445.
43. Seck T, Baron R, Horne WC. 2003. Binding of filamin to the C-terminal tail of the calcitonin receptor controls recycling. J. Biol. Chem. 278: 10408-10416.
44. Sjoblom T, et al. 2006. The consensus coding sequences of human breast and colorectal cancers. Science 314:268 -274.
45. Smith SC, et al. 2007. Expression of ral GTPases, their effectors, and activators in human bladder cancer. Clin. Cancer Res. 13:3803-3813.
46. Takala H, et al. 2008. Beta2 integrin phosphorylation on Thr758 acts as a molecular switch to regulate 14-3-3 and filamin binding. Blood 112:1853-1862.
47. Teller DC, Okada T, Behnke CA, Palczewski K, Stenkamp RE. 2001. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). 40: 7761-7772.
48. Thelin WR, et al. 2007. Direct interaction with filamins modulates the stability and plasma membrane expression of CFTR. J. Clin. Invest. 117: 364-374.
49. Tulipano G, et al. 2004. Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes. J. Biol. Chem. 279: 21374-21382.
50. Vernejoul F, et al. 2002. Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res. 62:6124-6131.
51. Wang P, DeFea KA. 2006. Protease-activated receptor-2 simultaneously directs beta-arrestin-1-dependent inhibition and Galphaq-dependent activation of phosphatidylinositol 3-kinase. Biochemistry 45:9374 -9385.
52. Wang Y, et al. 2007. A 90 kDa fragment of filamin A promotes Casodexinduced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells. Oncogene 26:6061-6070.
53. Weckbecker G, et al. 2003. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat. Rev. Drug Discov. 2:999-1017.
54. Xu Y, et al. 2010. Filamin A regulates focal adhesion disassembly and suppresses breast cancer cell migration and invasion. J. Exp. Med. 207: 2421-2437.
55. Yoshida N, et al. 2005. Filamin A-bound PEBP2beta/CBFbeta is retained in the cytoplasm and prevented from functioning as a partner of the Runx1 transcription factor. Mol. Cell. Biol. 25:1003-1012.
56. Zhang M, Breitwieser GE. 2005. High affinity interaction with filamin A protects against calcium-sensing receptor degradation. J. Biol. Chem. 280: 11140-11146.
57. Zhang SQ, et al. 2002. Receptor-specific regulation of phosphatidylinositol 3′-kinase activation by the protein tyrosine phosphatase Shp2. Mol. Cell. Biol. 22:4062- 4072.